Danaher stock gains after UBS starts coverage at USD 250
Published on 09/19/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Danaher Corp. stock (ISIN US2358511028) is tied to a fresh UBS call: according to MarketBeat on September 19, 2026, UBS started coverage on Danaher with a Buy rating and a USD 250 price target. MarketBeat also said the consensus rating was Moderate Buy, with an average target of USD 228.91.
Coverage and target gap
That target sits above the stock's recent range. MarketBeat said Danaher traded between USD 160.93 and USD 242.80 over the last 52 weeks, with a market cap of USD 148.74 billion.
For investors, the gap to the UBS target is the point: the implied upside is still there, but the share price has already moved close to the top of its yearly range.
Q1 numbers still matter
The latest operating base in the search set comes from Danaher's first quarter 2026 results. In the Q1 2026 transcript on Fortune, sales were USD 6 billion, core revenue rose 0.5 percent year over year, adjusted operating margin was 30.2 percent and adjusted diluted EPS was USD 2.06.
Free cash flow in Q1 2026 reached USD 1.1 billion, and management said adjusted full-year diluted net EPS guidance was raised to USD 8.35 to USD 8.55 from USD 8.35 to USD 8.50. The same transcript said core revenue growth for 2026 was still expected in a 3 percent to 6 percent range.
Stock near its range
Danaher stock is measured against those 2026 figures and the market's current valuation. YTD, the shares were down more than 7 percent in a September 18, 2026 comparison cited by Yahoo Finance, while the 52-week high of USD 242.80 remained close to the UBS target.
Danaher stock facts
- Company: Danaher Corp.
- ISIN: US2358511028
- Ticker: DHR
- Trading venue: NYSE
- Sector / Industry: Healthcare / Diagnostics & Research Tools
- Index membership: S&P 500
- Market capitalization: USD 148.74 billion
